Quick Takeaways
- Beutel, Goodman & Co Ltd. filed SCHEDULE 13G for EUPRAXIA PHARMACEUTICALS INC. Common Shares (EPRX).
- Disclosed ownership: 8%.
- Date of event: 30 Sep 2025.
Beutel, Goodman & Co Ltd. - 30 Sep 2025 SCHEDULE 13G Report for EUPRAXIA PHARMACEUTICALS INC. Common Shares (EPRX)
- Filing Manager
- Beutel, Goodman & Co Ltd.
- Reporting Manager
- Beutel, Goodman & Co Ltd.
- Symbol
- EPRX
- Shares outstanding
- 50,736,238 shares
- Disclosed Ownership
- 4,058,899 shares
- Ownership
- 8%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 09:10:51 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Beutel, Goodman & Co Ltd. disclosed 8% ownership in EUPRAXIA PHARMACEUTICALS INC. Common Shares (EPRX) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 09:10.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 8% | 4,058,899 | 3,899,519 | 0 | Michal Pomotov | CCO & General Counsel |